• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Optimer strips chairman of title, fires CFO and VP

Optimer strips chairman of title, fires CFO and VP

April 9, 2012
CenterWatch Staff

The board of directors of Optimer Pharmaceuticals, a San Diego-based biopharmaceutical company, has removed Michael Chang as chairman and terminated John D. Prunty, chief financial officer, and Dr. Youe-Kong Shue, vice president.

The board has appointed lead independent director Hank McKinnell as its new chairman and Kurt Hartman, who currently serves as general counsel, chief compliance officer and senior vice president, as acting CFO. A search for a permanent CFO has commenced.

The board, excluding Chang, unanimously approved the personnel changes. Optimer said that Chang remains as a director of the company, but that the board has requested his resignation.

The changes are not expected to materially impact the Optimer's revenues or operations, including the commercialization and launch of Dificid, but were related to certain lapses in corporate governance practices and the company's relationship with Optimer Biotechnology (OBI), its 43%-owned independent, Taiwan-based affiliate.

Chang's removal as chairman resulted from the board's views as to his actions in his capacity as Optimer's representative on the board of directors of OBI, as well as his failure to identify and effectively manage compliance, record keeping and conflict of interest issues in connection with OBI's grant to Chang—potentially for the benefit of a third party—of 1.5 million shares of OBI. The terminations of Prunty and Shue were related to the belief of Optimer's independent directors that both individuals failed to follow proper procedures when they became aware of the issues related to the issuance of the OBI shares to Chang.

"Clearly, we are disappointed that we had to take these actions,” said the newly-appointed McKinnell. “However, the board believes they reflect the importance to the company of good corporate governance practices and that they are in the best interests of the company and its stakeholders.”

Optimer said it has disclosed the matter to the relevant U.S. authorities and is cooperating with those authorities in reviewing the matter.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing